ESMO Congress 2019
A potential new targeted treatment for Notch mutation-positive tumours
A growing body of evidence has identified Notch mutations as a potential target in adenoid cystic carcinoma (ACC), a rare type of salivary gland carcinoma
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
Is tissue tumour mutational burden a predictive biomarker for immunotherapy in lung cancer?
Two post-hoc analyses of KEYNOTE studies presented at ESMO 2019
Precision medicine bursts onto the biliary tract cancer scene
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer